Continue to Site

Drug Discovery and Development

APC debuts ‘medicine accelerator’ in collaboration with Enterprise Ireland

By |

APC pharmaThe Dublin-based pharmaceutical R&D firm APC Ltd has launched a ‘Global Centre of Excellence for Vaccine and Advanced Therapeutic Research and Manufacturing.’

The result of a €25 million investment, the new facility will staff 120 new employees.

The facility will have the capacity to produce hundreds of millions of doses of vaccines (including for COVID-19) and other therapeutic products annually.

The new plant will link to supply chains in the U.S. and Europe. Approximately half of APC’s customers are based in the U.S. APC also owns an office in Boston. The trial involves some 400 patients. The protein-based vaccine uses a synthetic version of the SARS-CoV-2 spike protein.

APC is currently partnering with the Australian company Vaxine (Adelaide), which has a Phase 2 trial underway in Iran for a COVID-19 vaccine. Vaxine is a spin-off of Australia’s National Health Sciences Center.

APC facility

APC, an Irish pharmaceutical R&D company, debuts €25m investment and 120 jobs to accelerate development and manufacture of COVID-19 vaccines and other therapeutics. Shown here is Becca Dunne, process development engineer III.

APC’s ‘Global Centre of Excellence for Advanced Therapeutic and Vaccine Research and Manufacture’ will also draw support from Enterprise Ireland, the Irish government agency charged with driving the growth of Irish enterprises in global markets. In particular, Enterprise Ireland will support accelerated process development of vaccine candidates and other drug development at the new research facility. Enterprise Ireland will also offer strategic funding for VLE Therapeutics, a sister company of APC, to support the manufacturing of therapeutics and vaccines.

Some €8 million of APC’s total €25 million investment will cover the construction of an additional 12,000 sq ft laboratory and a 60,000 sq ft headquarters. The company expects the facilities to be operational by the end of June 2021.

The remaining $17 million will go to VLE Therapeutics to manufacture vaccines and advanced therapeutics, including cell and gene therapies.

 

Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
Tagged With: , , , , , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development